NewsBenzinga레볼루션 메디슨, 18.3개월 중간 추적 관찰에서 1차 치료 전이성 췌장암 환자 61명 대상 라손큐 플러스 화학요법의 확정 객관적 반응률 60.7%, 완전 반응 8.2% 확인···3상 RASolute 303 연구 지원 레볼루션 메디슨, 18.3개월 중간 추적 관찰에서 1차 치료 전이성 췌장암 환자 61명 대상 라손큐 플러스 화학요법의 확정 객관적 반응률 60.7%, 완전 반응 8.2% 확인···3상 RASolute 303 연구 지원 Benzinga 2026.11.20 05:38 (GMT+0) Open on Benzinga Other news Geospace Technologies (GEOS) Shares Tumble 16.47% After Hours: Here's Why Stock Market: Will S&P 500 Open Up or Down Today? Update: Geospace Technologies Q4 Adj. EPS $(0.86) Down From $(0.71) YoY, Sales $19.589M Down From $30.714M YoY Morning Bid: Anthropic's splashy IPO fails to lift AI boat Reported Earlier, Revolution Medicines’ RASONQUE Plus Chemotherapy Shows 60.7% Confirmed ORR, 8.2% Complete Responses In 61 First-Line Metastatic Pancreatic Cancer Patients At 18.3-Month Median Follow-Up; Supports Phase 3 RASolute 303 Onfolio Holdings (ONFO) Stock Drops 16.80% After Hours: Here's What Investors Should Know
Update: Geospace Technologies Q4 Adj. EPS $(0.86) Down From $(0.71) YoY, Sales $19.589M Down From $30.714M YoY
Reported Earlier, Revolution Medicines’ RASONQUE Plus Chemotherapy Shows 60.7% Confirmed ORR, 8.2% Complete Responses In 61 First-Line Metastatic Pancreatic Cancer Patients At 18.3-Month Median Follow-Up; Supports Phase 3 RASolute 303